Home › Research › Drug development
Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain
Butler PM, Francis A, Meunier AL, Anderson AK, Hennessey EL, Miller MB, Lemere CA, Selkoe DJ et al.. bioRxiv, 2025-05-21
Topic: Amyloid, tau and blood-test diagnosis
Importance Anti-amyloid immunotherapy is used to treat Alzheimer disease (AD) with moderate benefits and potentially serious side effects due to amyloid related imaging abnormality with effusions/edema (ARIA-E). Different anti-amyloid antibodies have different in vitro binding characteristics to different synthetic Aβ aggregates, leading to the assumption that they bind different species in the human brain. Lecanemab is hypothesized to bind “protofibrils,” but these are not well-characterized in human brain.
Key findings
- Different anti-amyloid antibodies have different in vitro binding characteristics to different synthetic Aβ aggregates, leading to the assumption that they bind different species in the human brain.
- Lecanemab is hypothesized to bind “protofibrils,” but these are not well-characterized in human brain.
- It is also unknown how binding differences correlate with ARIA-E rates.
- The APOE ε4 allele increases ARIA-E risk, but how it affects antibody binding characteristics is unknown.
Why it matters
This cross-sectional study examined how different anti-amyloid antibodies bind to Aβ aggregates from human Alzheimer disease brain, noting that lecanemab is hypothesized to bind protofibrils that are not well-characterized in human brain. It states that it is unknown how binding differences correlate with ARIA-E rates and how the APOE ε4 allele, which increases ARIA-E risk, affects antibody binding.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 26 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 24 of the 94 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (bioRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Andrew M. Stern: h-index 14 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 24 of the 94 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1101/2025.05.20.654902
- Original source →
- Free full text: bioRxiv (Cold Spring Harbor Laboratory) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Butler, P. M., Francis, A., Meunier, A. L., Anderson, A. K., Hennessey, E. L., Miller, M. B., et al. (2025). Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain. bioRxiv. https://doi.org/10.1101/2025.05.20.654902
Vancouver
Butler PM, Francis A, Meunier AL, Anderson AK, Hennessey EL, Miller MB, et al. Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain. bioRxiv. 2025. doi:10.1101/2025.05.20.654902.
BibTeX
@article{butler2025-35ab99e8,
author = {Butler, P. M. and Francis, A. and Meunier, A. L. and Anderson, A. K. and Hennessey, E. L. and Miller, M. B. and Lemere, C. A. and Selkoe, D. J. and others},
title = {{Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain}},
journal = {bioRxiv},
year = {2025},
doi = {10.1101/2025.05.20.654902},
url = {https://doi.org/10.1101/2025.05.20.654902}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development
Also tagged “amyloid-beta”
1,339 studies in the library carry the topic tag “amyloid-beta”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.